Adding the investigational new drug, MET inhibitor savolitinib, to EGFR inhibitor osimertinib imporved clinical response in patients with EGFR-mutant non-small cell lung cancer (NSCLC) which is resistant to previous EGFR-targeted therapies through MET-gene amplification, according to interim results from two expansion cohorts of the phase Ib clinical trial TATTON, presented at the AACR Annual Meeting 2019.
"To date, targeted therapy for lung cancer patients with EGFR mutations has consisted ...
Adding the investigational new drug, MET inhibitor savolitinib, to EGFR inhibitor osimertinib imporved clinical response in patients with EGFR-mutant non-small cell lung cancer (NSCLC) which is resistant to previous EGFR-targeted therapies through MET-gene amplification, according to interim results from two expansion cohorts of the phase Ib clinical trial TATTON, presented at the AACR Annual Meeting 2019.
"To date, targeted therapy for lung cancer patients with EGFR mutations has consisted ...